BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Ultimate Trader

1 year 40%, 2 years 50% and *3 years 60%

*Across 3 years $3395.52 only $1358.21

ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,997.56
      0.47%
      US Tech 100
      20,296.00
      0.32%
      Dow Jones
      44,715.04
      0.94%
      Brent Oil
      72.825
      -2.60%
      Bitcoin
      96,082.80
      -2.01%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. AtriCure Inc (ATRC) Quote

      AtriCure Inc

      AtriCure Inc (ATRC)

      NASDAQ
      35.86
      0.125
      ( 0.35% )
      Updated: 10:31:24
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      35.86
      Bid
      35.86
      Ask
      36.02
      Volume
      51,533
      35.43 Day's Range 36.24
      18.94 52 Week Range 42.985
      Market Cap
      1.748B
      Previous Close
      35.735
      Open
      36.155
      Last Trade
      7
      @
      36
      Last Trade Time
      10:32:54
      Financial Volume
      $ 1,850,849
      VWAP
      35.9158
      Average Volume (3m)
      580,933
      Shares Outstanding
      48,753,251
      Dividend Yield
      -
      PE Ratio
      -57.90
      Earnings Per Share (EPS)
      -0.62
      Revenue
      399.25M
      Net Profit
      -30.44M

      About AtriCure Inc

      AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft T... AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. Show more

      Sector
      Surgical,med Instr,apparatus
      Industry
      Surgical,med Instr,apparatus
      Website
      www.atricure.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      AtriCure Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker ATRC. The last closing price for AtriCure was $35.74. Over the last year, AtriCure shares have traded in a share price range of $ 18.94 to $ 42.985.

      AtriCure currently has 48,753,251 shares outstanding. The market capitalization of AtriCure is $1.74 billion. AtriCure has a price to earnings ratio (PE ratio) of -57.90.

      Ask ADVFN Intelligence (AI)

      ATRC Latest News

      More News

      AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

      AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

      November 20 2024
      Business Wire

      Form SC 13G - Statement of Beneficial Ownership by Certain Investors

      November 14 2024
      Edgar (US Regulatory)

      AtriCure to Participate in the Stifel 2024 Healthcare Conference

      AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

      November 07 2024
      Business Wire

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      October 30 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      October 29 2024
      Edgar (US Regulatory)

      AtriCure Reports Third Quarter 2024 Financial Results

      Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year Achieved 20% growth on revenues from open appendage...

      October 29 2024
      Business Wire

      AtriCure to Participate in the UBS Global Healthcare Conference

      AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

      October 28 2024
      Business Wire

      AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management

      AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

      October 15 2024
      Business Wire

      AtriCure to Announce Third Quarter 2024 Financial Results

        AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain...

      October 08 2024
      Business Wire

      AtriCure a obtenu la certification de marquage CE pour la pince EnCompass®

      Une approbation qui sert de nouveau vecteur de croissance à l'international pour AtriCure AtriCure, Inc. ( Nasdaq: ATRC ), leader en matière d'innovation pour les interventions chirurgicales et...

      October 01 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.952.7212832999134.9136.44534.1541164035.64652883CS
      47.6126.938053097328.2538.3427.7173577934.31671063CS
      1210.0338.830816879625.8338.3425.49558093330.60865009CS
      2612.3852.725724020423.4838.3418.9471874725.74565674CS
      52-5.94-14.210526315841.842.98518.9471076728.02282309CS
      156-39.33-52.307487697875.197718.9443393536.88959481CS
      2606.8523.612547397429.0189.1818.9439924142.32994344CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      QMCOQuantum Corporation
      $ 22.78
      (149.51%)
      		13.45M
      RGTIRigetti Computing Inc
      $ 3.3388
      (91.89%)
      		154.71M
      XCURExicure Inc
      $ 27.58
      (50.05%)
      		878.47k
      ARQQArqit Quantum Inc
      $ 19.335
      (49.65%)
      		1.59M
      OPIOffice Properties Income Trust
      $ 1.675
      (47.58%)
      		2.48M
      SAVACassava Sciences Inc
      $ 3.978
      (-84.98%)
      		46.57M
      CMAXCareMax Inc
      $ 0.48485
      (-32.66%)
      		1.6M
      ONCTOncternal Therapeutics Inc
      $ 0.7689
      (-32.55%)
      		220.51k
      VRPXVirpax Pharmaceuticals Inc
      $ 0.4169
      (-26.47%)
      		4.23M
      SHOTWSafety Shot Inc
      $ 0.112
      (-25.33%)
      		800
      RGTIRigetti Computing Inc
      $ 3.3388
      (91.89%)
      		154.71M
      ELABElevai Labs Inc
      $ 0.01575
      (-21.64%)
      		123.65M
      CTXRCitius Pharmaceuticals Inc
      $ 0.141
      (5.38%)
      		103.23M
      NVDANVIDIA Corporation
      $ 137.22
      (-3.33%)
      		80.67M
      QMMMQMMM Holdings Limited
      $ 1.0901
      (45.37%)
      		70.49M

      ATRC Discussion

      View Posts
      mlkrborn mlkrborn 11 years ago
      HISTORY
      Initial Public Offering



      On August 10, 2005, we consummated an initial public offering of 4.6 million shares of our common stock at $12.00 per share, which includes the underwriters exercise of their over-allotment option, on August 9, 2005, to purchase 600,000 shares of our common stock of which 450,000 shares were sold by selling shareholders and 150,000 shares were sold by us. We did not receive any proceeds from the sale of the 450,000 shares of common stock that were sold by selling shareholders. These share amounts reflect a 1-for-3.8 reverse split of our capital stock that was effected on July 27, 2005. Proceeds to us from the offering, after deducting underwriting discounts and commissions but before expenses, were $46.3 million. Expenses are estimated to be approximately $3.25 million.



      15
      👍️0
      mlkrborn mlkrborn 11 years ago
      AtriCure receives FDA approval for investigational study to evaluate stroke prevention in atrial fibrillation (ATRC) 14.35 : Co announces the FDA approval to begin enrollment in a clinical study of AtriCure's AtriClip Left Atrial Appendage Exclusion System. The study will evaluate the use of the AtriClip device to prevent stroke in patients with Afib. The feasibility study will enroll Afib patients at seven medical centers across the country. The study will focus on patients with risk factors that place them at significant risk of stroke as well as substantial bleeding risks that contraindicate them for anticoagulation therapy. Research suggests that up to 40% of patients are unable to take oral anticoagulants due to excessive risk of bleeding.
      👍️0
      dmarkg dmarkg 12 years ago
      Hey Wobblenuts and Jackie Scan I want to show you something....

      Medical Breakthrough Wound Stasis Technology

      ATRC and EPGL could possibly go hand in hand here...
      Merry Christmas 2012

      Merry Chirstmas 2012, friends.
      👍️0
      wobblenuts wobblenuts 12 years ago
      Any talks involving ATRC and soon to be sub penny wonder EPGL?



      Are they hinting at something here?


      1)"ATRC fully SEC reporting financials are available at OTCMARKETS for EPGL investors to see as an example of where EPGL management is headed."

      2)"EPGL initiating R&D on 4 new medical devices before end of 2012."

      3)"Property and equipment, net 0"
      👍️0
      Penny Roger$ Penny Roger$ 13 years ago
      ~ Monday! $ATRC ~ Earnings posted, pending or coming soon! In Charts and Links Below!

      ~ $ATRC ~ Earnings expected on Monday *
      Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
      One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








      http://stockcharts.com/h-sc/ui?s=ATRC&p=D&b=3&g=0&id=p88783918276&a=237480049




      http://stockcharts.com/h-sc/ui?s=ATRC&p=W&b=3&g=0&id=p54550695994



      ~ Google Finance: http://www.google.com/finance?q=ATRC
      ~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=ATRC#
      ~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=ATRC+Key+Statistics
      ~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=ATRC
      Finviz: http://finviz.com/quote.ashx?t=ATRC
      ~ BusyStock: http://busystock.com/i.php?s=ATRC&v=2


      <<<<<< http://www.earningswhispers.com/stocks.asp?symbol=ATRC >>>>>>



      http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

      *If the earnings date is in error please ignore error. I do my best.
      👍️0
      Penny Roger$ Penny Roger$ 13 years ago
      AtriCure, Inc., is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues, is Isolator Synergy bipolar ablation clamp system (Isolator system) and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage.

      http://www.google.com/finance?q=ATRC
      👍️0

      Your Recent History

      NASDAQ
      ATRC
      AtriCure
      Delayed Upgrade Clock